Pharmacology Watch
RSSArticles
-
CDC Calls for Two-shot HPV Regimen
Recent studies have shown if the first shot is administered before age 15, two shots confer immunity.
-
New Research Supports Safety of Receiving Vital Vaccination During Pregnancy
Infants exposed to combined tetanus, diphtheria, and acellular pertussis vaccinations were no more likely to develop structural birth defects, including microcephaly, than offspring of unvaccinated mothers.
-
FDA Actions
In this section: FDA removes black box warning from Chantix; approves first biosimilar to Humira; issues warning about hepatitis C drug; and green lights first drug to treat common childhood form of muscular dystrophy.
-
Experts Withdraw Support for Codeine in Children
After years of debate, the American Academy of Pediatrics has issued a Clinical Report recommending against the use of codeine for cough or pain in children, regardless of age.
-
New Erectile Dysfunction Data Counter Previous Studies
This study will be a relief for men who take 5-alpha reductase inhibitors, since previous studies suggested erectile dysfunction may be a significant problem with these drugs.
-
New Study Compares Leading Atrial Fibrillation Treatments
The authors concluded that rivaroxaban use for atrial fibrillation was associated with significantly higher rates of intracranial hemorrhage and major extracranial bleeding.
-
FDA Actions
In this section: FDA warns of potential lethal outcomes regarding potent drug combination, approved first biosimilar to etanercept for multiple inflammatory diseases, and bans specific chemicals in certain consumer antiseptic wash products.
-
Two Flu Vaccines Show Comparable Efficacy
Study shows two vaccines were of equal efficacy, at least in preventing influenza.
-
Connecting Calcium Supplementation to Dementia in Elderly Women
While derived from a small sample, data suggest calcium supplementation may increase the risk of developing dementia in elderly women with cerebrovascular disease.
-
Report: Certain Cholesterol-lowering Drugs Too Expensive
Manufacturers of these drugs would need to reduce the annual cost by nearly $10,000 per year, from $14,000 to about $4,500, to make them cost effective.